维思通治疗首发精神分裂症的疗效分析

目的：观察维思通治疗首发精神分裂症的疗效和副反应。方法：单独使用维思通治疗连续住院的首发精神分裂症12周，用BPRS和TESS量表评定疗效和副反应。结果：115例首发精神分裂症患者完成12周治疗，其显效41例（35．7％），有效68例（59．1％），无效6例（5．2％），副反应均较轻微。结论：维思通治疗精神分裂症安全有效，是治疗首发精神分裂症的首选药物。

A clinical study of risperidone in the treatment of first - onset schizophrenia

Objective To examine the clinical efficacy and side effect of risperidone in the treatment of first-onset schizophrenia.Method Patients with first-onset schizophrenia were treated with risperidone for 12 weeks,and assessed with BPRS and TESS for the efficacy and side effect.Results Of 115 cases who completed the treatment,41 cases(35.7%) were significantly improved,68 cases(59.1%)improved and 6 cases(5.2%)had no response.The side effect was mild.Conclusion It is suggested that risperidone is both effective and safe in the treatmnet of schizophrenia and should be regarded as the first choice for patients with first-onset schizophrenia.